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Abstract
Background: Excitation/inhibition (E/I) imbalance remains a widely discussed hypothesis in autism spectrum disorders
(ASD). The presence of such an imbalance may potentially define a therapeutic target for the treatment of cognitive
disabilities related to this pathology. Consequently, the study of monogenic disorders related to autism, such
as neurofibromatosis type 1 (NF1), represents a promising approach to isolate mechanisms underlying ASD-
related cognitive disabilities. However, the NF1 mouse model showed increased γ-aminobutyric acid (GABA)
neurotransmission, whereas the human disease showed reduced cortical GABA levels. It is therefore important
to clarify whether the E/I imbalance hypothesis holds true. We hypothesize that E/I may depend on distinct
pre- and postsynaptic push-pull mechanisms that might be are region-dependent.
Methods: In current study, we assessed two critical components of E/I regulation: the concentration of
neurotransmitters and levels of GABA(A) receptors. Measurements were performed across the hippocampi,
striatum, and prefrontal cortices by combined in vivo magnetic resonance spectroscopy (MRS) and molecular approaches
in this ASD-related animal model, the Nf1+/− mouse.
Results: Cortical and striatal GABA/glutamate ratios were increased. At the postsynaptic level, very high receptor GABA(A)
receptor expression was found in hippocampus, disproportionately to the small reduction in GABA levels. Gabaergic tone
(either by receptor levels change or GABA/glutamate ratios) seemed therefore to be enhanced in all regions, although by
a different mechanism.
Conclusions: Our data provides support for the hypothesis of E/I imbalance in NF1 while showing that pre- and
postsynaptic changes are region-specific. All these findings are consistent with our previous physiological evidence of
increased inhibitory tone. Such heterogeneity suggests that therapeutic approaches to address neurochemical imbalance
in ASD may need to focus on targets where convergent physiological mechanisms can be found.
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Background
The E/I imbalance hypothesis, conceptualized as a disequi-
librium between the glutamatergic and γ-aminobutyric
acidergic (GABAergic) inputs, has been postulated to
underlie brain dysfunction across neurodevelopmental and
neuropsychiatric disorders, including autism spectrum dis-
order (ASD) and schizophrenia (SCZ) [1, 2]. According to
this framework, changes in the balance between these neu-
rotransmitters impact excitation/inhibition ratios altering
brain activity patterns and resulting in behavioral and cog-
nitive impairments. In the wide range of autism spectrum
disorders (ASD), neurofibromatosis type 1 (NF1) is a rele-
vant model to study this hypothesis. This common mono-
genic developmental disorder, characterized by altered skin
pigmentation and increased tumor predisposition, is associ-
ated with macrocephaly and T2-weighted hyperintensities
[3]. Consequently, children with NF1 commonly show cog-
nitive deficits in visuospatial, motor, language, and memory
domains leading to significant delays in neurodevelopmen-
tal milestones and often reduced intelligent quotient (IQ)
[4, 5]. The similarities between the cognitive phenotypes of
NF1 and idiopathic ASD make this single-gene disorder a
relevant model of syndromic autism [6, 7].
NF1 is caused by a single mutation of the Nf1 gene that
encodes for neurofibromin, a negative regulator of the
RAS pathway. This protein is expressed in both neurons
and glia and is required for the regulation of cellular
growth and differentiation [3]. Previous studies employing
a mouse model of NF1 demonstrated that γ-aminobutyric
acid (GABA) inhibition was enhanced in the hippocampus
due to excessive RAS activity caused by mutations in the
Nf1 gene [8–12]. These alterations in GABA neurotrans-
mission were associated with learning and memory defi-
cits [8–12]. In humans, we have found that excitation/
inhibition balance is altered in the visual and medial
frontal cortex of patients with NF1, as a consequence of
reduced GABA concentration [13, 14]. More recently, we
observed a decreased binding of GABA(A) receptors
(GABA(A)R) in patients in the parieto-occipital cortex,
midbrain, and thalamus suggesting neurodevelopmental
synaptopathy both at the pre- and postsynaptic level [15,
16]. However, levels of GABA and GABA(A)R have never
been assessed in NF1 mutant mice, which is important to
link the preclinical model to clinical observations and to
the development of therapies targeting GABAergic path-
ways. For example, picrotoxin, a GABA(A)R inhibitor, has
been shown to reverse learning deficits in the NF1 mouse
model [9, 10]. Overall, although both animal and human
studies demonstrate an excitation/inhibition imbalance in
NF1, the nature of such disequilibrium remains to be
understood, both across species and brain regions.
The present aimed to directly test the E/I imbalance
hypothesis in an animal model of NF1. We focused on
two critical elements contributing to the E/I balance: (1)
the concentration of GABA, the main inhibitory neuro-
transmitter, and glutamate, the main excitatory neuro-
transmitter; (2) the postsynaptic levels of the GABA(A)
receptor. In an effort to close the gap between preclin-
ical models and human disease, the concentration of
neurotransmitters was assessed using magnetic reson-
ance spectroscopy (MRS), the same technique as avail-
able to measure GABA levels in vivo in humans. This
was then combined with cellular/molecular approaches
with the aim of providing a comprehensive view of syn-
aptic function, by investigating GABA(A) receptor levels.
We focused on three brain regions, the hippocampus,
prefrontal cortex, and striatum, as these regions have
previously been shown by us and others to be affected in
the NF1 model, leading to increased inhibitory activity,
and in patients [8–10, 14, 16].
Our findings suggest region-specific imbalances which
involve GABA pools and receptor levels. The fact that
E/I imbalance is of a distinct nature at different brain re-
gions, although all leading to increased inhibitory drive,
suggests that therapeutic approaches to restore E/I bal-
ance need to address this regional heterogeneity, pos-
sibly by choosing upstream targets.
Methods
Animals
Fourteen Nf1+/− mice were used in the experiments;
these mice were obtained from animals backcrossed to
Taconic C57Bl/6 mice at least 10 times and bred once
with 129T2/SvEmsJ before experiments. This breeding
procedure was put in place to keep the genetic back-
ground of the Nf1+/− mice constant across experiments
and studies [17, 18]. Seven- to eight-month-old male and
female mice were used. All experiments used littermates
as controls (n = 13) and were carried and analyzed with
the experimenters blinded to genotype and treatment. An-
imals were group housed (2–4) on a 12-h light/dark cycle
in vivarium at UCLA, CAU, and CNC.IBILI. The experi-
ments were carried out in accordance with the European
Union Council Directive (2010/63/EU), the National Reg-
ulations, and the Internal Review Board of the University
of Coimbra. Experimental protocols at the University of
California were approved by the Chancellor’s Animal
Research Committee of the University of California,
Los Angeles, in accordance with NIH guidelines. All in-
cluded animals were healthy (discomfort score 0), and
all efforts were made to minimize the number of ani-
mals used and their suffering.
1H-MRS
Acquisitions were performed on a 9.4T MR pre-clinical
scanner (Bruker Biospec, Billerica MA) equipped with a
standard Bruker crosscoil setup using a volume coil for
excitation (86/112 mm of inner/outer diameter) and
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quadrature surface coil for detection (Bruker Biospin,
Ettlingen, Germany). Mice were anesthetized by inhalation
of 1.5% isoflurane with 100% O2 and placed on
temperature-controlled animal beds. A tooth bar and head
restrain were used to reduce motion artifacts. Physiological
parameters were continuously monitored and body
temperature was maintained at 37 °C using a mouse heat-
ing cover (Bruker Biospin, Ettlingen, Germany). To assure
accurate voxel positioning, we first obtained T2-weighted
images in axial, coronal, and sagittal planes using a rapid
multi-slice acquisition refocusing echoes (RARE) sequence
directions with the following parameters: repetition time
(TR) = 2500 ms, echo time (TE) = 33 ms, matrix size
256 × 256, field of view 20 × 20 mm2, 22 slices, slice
thickness = 0.5 mm, RARE factor = 8, and 1 average. First-
and second-order shims were adjusted using the fieldmap-
based MAPSHIM routine, leading to water linewidths
between 14 and 20 Hz. MRS voxels were positioned in
three locations: striatum (1.8 × 2.0 × 2.2 mm), hippo-
campus (1.9 × 1.3 × 1.9 mm), and pre-frontal cortex
(2.0 × 1.2 × 2.0 mm). Spectra were acquired using a point-
resolved spectroscopy (PRESS) sequence with outer volume
suppression (OVS) and VAPOR water suppression [19, 20].
The following parameters were used: TR = 2500 ms,
TE = 16,225 ms, number of averages = 720, 3 flip an-
gles = 90°, 142°, 142°, bandwidth = 5000 Hz, number of ac-
quired points = 2048 yielding a spectral resolution of
1.22 Hz/pt. Total acquisition time was 30 min. Before each
spectrum, we acquired an unsuppressed water spectrum at
the same voxel location (TE = 16,225 ms, TR = 2500 ms,
16 averages, scanning time = 40 s). Data analysis of 1H-
MRS spectra was performed using linear combination
modeling LCModel (Stephen Provencher Inc., Toronto,
Canada) [21]. Metabolite quantification was performed ap-
plying the internal water reference method. Concentrations
in millmole units were calculated for metabolites, and re-
sults are presented in institutional units (i.u.). Only metabo-
lites with Cramér–Rao bounds < 20% were considered for
statistical analysis.
Western blot
Mice were sacrificed following the 1H-MRS procedure.
Brains from half of the animals (7 Nf1+/− and 7 WT mice)
were removed, and the hippocampi, prefrontal cortex, and
striata were dissected on ice, to isolate the synaptossomal
fraction using Syn-PER Synaptic Protein Extraction Re-
agent (Thermo Scientific, Pierce Biotechnology, Rockford,
USA) according to the manufacturer’s instructions. The
protein fraction was then quantified using the BCA
method and stored at − 80 °C until further use. The pro-
teins were separated on SDS-polyacrylamide gel elec-
trophoresis and transferred onto polyvinylidine difluoride
membrane (PVDF; Milipore, Madrid, Spain). After
blocked, membranes were incubated with anti-GABA(A)R
α1 (1:1000; ref. AGA-001 from Alomone Labs, Jerusalem,
Israel), washed and then incubated with alkaline
phosphatase-conjugated secondary antibodies (1:20,000;
ref. RPN4301 from Amersham, GE Healthcare Life Sci-
ence, USA) and visualized using ECF reagent (Amersham)
on Typhoon FLA 9000 (GE Healthcare Bio-Science AB,
Uppsala, Sweden). Immunoblots were reprobed with β-
actin antibody (1:10,000; ref. A5441 from Sigma-Aldrich)
to ensure equal sample loading, and densitometric ana-
lyses were performed using the NIH ImageJ 1.44 analysis
software.
Immunohistochemistry
Following imaging analysis, the other half of animals
(7 Nf1+/− and 6 WT mice) were sacrificed and their
brains were removed, frozen on dry ice, and stored at
− 80 °C. Coronal sections (14 μm) were cut on a
cryostat (Thermo Shandon Inc.) from the posterior to
anterior brain. Before starting the immunohistochem-
istry procedure, the brain slices were fixed in 4%
paraformaldehyde (PFA). Then, immunolabeling was
performed for the GABA(A)α1 receptor subunit.
Briefly, brain sections were rinsed, blocked, and incu-
bated with anti-GABA(A)α1 (1:2000; ref. AGA-001
from Alomone Labs). Brain slices were then washed
and incubated with Alexa Fluor 488 anti-rabbit sec-
ondary antibody (1:200; ref. ab150077 from Invitro-
gen, Inchinnan, Business Park, UK). Sections were
again washed and stained with Hoechst 33342 (5 μg/
mL; ref. 94403 from Sigma-Aldrich), mounted in
Dako fluorescence medium (Dako North America,
Carpinteria, USA), and images were recorded using
LSM 710 Meta Confocal microscope (Carl Zeiss,
Oberkochen, Germany). The quantification of fluores-
cence intensities of GABA(A)α1 receptor labeling was
performed using the NIH Fiji ImageJ 2.0.0 analysis
software.
Statistics
Data are expressed as mean ± SEM and are statistically dif-
ferent at p < 0.05. Statistical analysis was performed using
the Mann-Whitney test in GraphPad Prism 6.0 (GraphPad
software, Inc., San Diego, CA, USA). Additionally, statistical
comparisons concerning metabolite concentrations for each
brain region were controlled for using the Benjamini-
Hochberg false discovery rate procedure.
Results
NF1 depletion induces region-specific alterations in
GABA and glutamatergic systems. MRS was performed
in the hippocampus, prefrontal cortex, and striatum of
Nf1+/− mutant and wild-type (WT) controls (Fig. 1). We
investigated whether the GABA/glutamate ratio was al-
tered in Nf1+/−, which is an index of the local balance
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between excitation and inhibition. We found a signifi-
cant increase in the GABA/glutamate ratio in the mu-
tant prefrontal cortex (p = 0.015) and striatum
(p = 0.026), but not in the hippocampus (Fig. 1g). In
absolute terms, Nf1+/− animals showed a small (in
comparison to the effect size of local increases in
GABAR, see below) but significant decrease in hippo-
campal GABA levels (p = 0.004), without significant
differences in other analyzed brain regions (Fig. 1).
Additionally, hippocampal (p = 0.006) and striatal
(p = 0.035) glutamate levels of mutant mice were re-
duced (Fig. 1b, f ), without changes in cortical levels
(Fig. 1d).
Nf1+/− mutation modulates GABA(A) receptor levels in a
brain region-specific manner
Given the demonstration that NF1-associated learning
deficits are rescued by a GABA(A) antagonist [9], and our
recent study in humans suggesting postsynaptic GABA
changes [15], it was important to verify the impact of NF1
depletion on GABA(A) R levels. We found that NF1 is as-
sociated with a profound pattern of modification in
GABA(A) R binding that seems to be region specific. Hip-
pocampal receptor content was significantly increased in
the synaptosomal compartment (p = 0.0270) (Fig. 2a, b).
On the contrary, synaptossomes of Nf1+/− prefrontal
cortex showed reduction in GABA(A) R α1 protein levels
(p = 0.0012) as compared to WT (Fig. 2a, b). No changes
were detected in the striatum (Fig. 2a, b). These results
were corroborated by immunohistochemistry studies, as
shown in Fig. 3a. Our results showed again a significant,
with a quite large effect size, increase of immunoreactivity
of GABA(A) R α1 in Nf1+/− hippocampal sub-regions,
dentate gyrus (DG), and cornu ammonis 1 (CA1) and 3
(CA3; p = 0.0002), while cortical (p = 0.0286) brain slices
exhibited immunoreactivity reduction (Fig. 3a). Further-
more, in the striatum, we observed formation of clusters
surrounded by hypodense regions and reduction of
GABA(A) R-expressing cells suggesting redistribution of
these molecules to these hiperdense clusters (p = 0.0286;
Fig. 3a). These results were confirmed by immunoreactiv-
ity quantification in all analyzed brain regions (Fig. 3b).
Discussion
In this preclinical study, we found evidence for distinct
pre- and postsynaptic phenotypes supporting the E/I im-
balance hypothesis in ASD and related neurodevelopmen-
tal disorders but in a region-dependent manner. An
important motivation was the identification of biological
mechanisms in ASD and their putative heterogeneity be-
cause this is important for the design of adequate thera-
peutic strategies [22]. Monogenic disorders where a
physiological link for impaired inhibition is present, such
as NF1, are relevant models in this context [7]. Both in
NF1 and idiopathic ASD, the hypothesis of E/I imbalance
have been widely debated [8, 9, 13, 14, 23], and recent re-
views summarize the convergence of E/I patterns in
autism and schizophrenia, based on physiological and
genetic evidence [1, 2]. However, in spite of the current
trend to consider autism and schizophrenia as sharing
molecular, synaptic, and systems targets that are common
to both disorders, significant distinctions should also be
Fig. 1 Nf1+/− mutation induces imbalance of excitatory/inhibitory systems. Localization of the magnetic resonance spectroscopy (MRS) voxel (blue
square) in the hippocampus (HIP; a), prefrontal cortex (PFC; c), and striatum (STR; e) of representative Nf1+/− mice. GABA and glutamate levels in
hippocampus (b), prefrontal cortex (d), and striatum (f) of wild-type (black circle) and Nf1+/− (gray circle) mice. MRS measurements revealed that
hippocampal GABA and glutamate concentration are decreased (b) as well as striatal levels of glutamate (f). However, no changes are found in Nf1+/−
prefrontal cortex (d). The analyses indicated an upregulation of the GABA/glutamate ratio in mutant prefrontal cortex and striatum (g). Graphs depict
individual values, mean, and standard error (n = 12–14). *p < 0.05, **p < 0.01, ***p < 0.001, statistical significance using the Mann-Whitney’s test
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considered. Moreover, although NF1 is well recognized as
a single-gene model for autism [10], this notion should be
put into the context of the large heterogeneity of ASD.
Here, we combined MRS, a technique previously only
used in human studies, with molecular/cellular
approaches, to study the hypothesis of E/I imbalance at
both pre- and postsynaptic levels. We have found that
the Nf1+/− mutation disrupted the E/I balance in a
region-specific manner. Future studies should address
whether this can be generalized to other ASDs and
examine further whether this conceptual framework is
valid across species. In particular, we discovered that
the nature of E/I imbalance in hippocampus, striatum,
and prefrontal cortex of mouse NF1 model presents
distinct sources in spite of the presence of increased in-
hibitory drive in all these regions, shown in our previ-
ous work [9, 10]. These observations may be crucial to
interpret the differences between the animal model and
the manifestations of the human disease.
Overall, we found that the ratio of GABA/glutamate is
increased in the cortex and striatum of our animal
model. The hippocampus did not show ratio changes
but instead a disproportionate increase in GABA(A)R
levels in spite of the small reduction of GABA levels. All
these distinct cross-regional differences are consistent
with increased inhibitory drive that is present in all these
regions, as found in our previous work. These findings
and their conceptual implications are summarized in
Fig. 4.
Some care should be taken when considering absolute
concentrations in the context of cross species compari-
sons. Although hippocampal reductions in the levels of
GABA and glutamate match our observations in adults
with NF1 [16], they are at odds with similar cortical
alterations observed in patients but absent in mice.
Future work should establish whether the relation
between regional E/I dysfunction and the pattern of defi-
cits found in human NF1 subjects also holds true in
Fig. 2 The NF1 mouse brain shows regional changes in GABA(A) α1 subunit receptor levels. Western blot analyses demonstrated that expression
levels of GABA(A) receptor is up- and downregulated in hippocampal and cortical synaptosomes (a), respectively. Representative Western blot
images of GABA(A)α1 receptor (50 kDa) and β-actin (42 kDa) are shown (b). Data are expressed as mean ± SEM (n = 8–14). *p < 0.05, statistical
significance comparing with respectively wild-type using the Mann-Whitney’s test
Fig. 3 Nf1+/− mutation induced regional changes in GABA(A) α1 subunit receptor pattern. GABA(A) receptor immunoreactivity (red; Hoescht
33342—blue) was altered in Nf1+/− mice hippocampus, prefrontal cortex, and striatum, with substantial hippocampal increases, independently
confirming the results shown in Fig. 2, and with reductions in the other regions, with a patchy pattern in the striatum (with both hypodense
and hyperdense regions) (a). Accordingly, quantification of respective fluorescence intensity (b) demonstrated that the NF1 induced significant
GABA(A) receptor augmentation in hippocampus while prefrontal cortex and striatum showed a downregulation. Data are expressed as
mean ± SEM (n = 8–14). *p < 0.05, ***p < 0.001, statistical significance comparing with respectively wild-type using the Mann-Whitney’s test.
Scale bar, 20 μm
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cross-species comparisons. This was suggested to be
the case in hippocampal-dependent learning impair-
ments, visual orientation discrimination deficits, and
impaired impulse control that depends on corticos-
triatal circuits [3, 13, 24].
In mice, deficits in executive, social, spatial memory,
and attention have been associated with an increase in
GABAergic neurotransmission, which dampens synaptic
plasticity, in the hippocampus, pre-frontal cortex, stri-
atum, and amygdala [8–12]. On the other hand, in NF1
patients, a decrease in GABA levels has been observed
in all so far tested cortical regions [13, 14]. Here, we
found that GABA and glutamate levels as well GABA(A)
R expression were critically and differentially changed
across regions. Differential levels of brain amino acids
have been reported in several neuropsychiatric disorders
[25, 26], and two recent reviews have focused on conver-
gence and divergence of E/I phenotypes in ASD and
schizophrenia [1, 2].
The inhibitory actions of central GABA are mediated in
part by the ionotropic post-synaptic GABA(A)R [27]. Our
data demonstrated that hippocampal levels of GABA(A)
R were increased in the synaptosomal compartment
suggesting increased inhibitory tone, corroborating
physiological data from our previous work [9, 10]. Further,
our results are similar to those observed in schizophrenic
patients, showing a reduction in cortical GABA content
coupled with the increased expression of GABA(A) R
[28]. Despite its limitations, MRS is an important in vivo
technique to address neurotransmitter changes. With this
technique, it has been possible to show that global [29]
and local [15] GABA levels can be related to GABA recep-
tor concentrations.
In line with this evidence, previous neurophysiological
studies that demonstrated that NF1-dependent learning
deficits are caused by increased pre-synaptic GABA re-
lease that consequently disrupts long-term potentiation,
with involvement of the GABA(A) R [8–12]. In the pre-
frontal cortex, the synaptic phenotype seems to be quite
different to what was observed in the hippocampus. These
results are important to understand our own previous
studies which showed that NF1 affects the inhibitory sys-
tem most prominently by regulating activity-dependent
GABAergic release in medial prefrontal cortex [10]. More-
over, in the same study, we found that the striatum of Nf1
+/− mice shows an activity-dependent increase in the fre-
quency of inhibitory but not excitatory events. These find-
ings are consistent with hypoactivation of corticostriatal
Fig. 4 Summary of regional phenotypes of excitation/inhibition imbalance in the mouse model of neurofibromatosis type 1. The Nf1+/− model
shows GABAergic changes in a region-dependent way. The synaptic phenotype in hippocampus is characterized by GABA(A) R disproportionate
increases while in the prefrontal cortex and striatum it is characterized by GABA/glutamate ratio increases. In spite of the differences in synaptic phenotype
in these brain regions, the physiological phenotype is similar with converging increases of sIPSCs relative to sEPSCs resulting in increased inhibitory drive.
Abbreviation: GABA, γ-aminobutyric acid; GLU, glutamate; sEPSCs, spontaneous excitatory post-synaptic currents; sIPSCs, spontaneous
inhibitory post-synaptic currents
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structures that are observed in humans and directly
related with working memory impairments characteris-
tic of NF1 [10].
As a limitation, the E/I imbalance hypothesis in ASD
and related neurodevelopmental disorders, although
widely accepted as a valid and testable conceptual frame-
work [1, 2], may represent an oversimplification and
need refinement. Future work should directly address in
vivo assessment of the dependence of excitatory and in-
hibitory drive on changes of the molecular phenotype at
the level of the synapse.
Conclusions
In this preclinical study, we found a relationship
between tissue levels of metabolites and receptor expres-
sion in a condition where there is disruption to E/I at
various levels. This provides evidence in favor of the E/I
imbalance hypothesis ASD and related neurodevelop-
mental disorders, while showing that its nature is
region-specific with distinct pre- and postsynaptic mech-
anisms. In the hippocampus, disproportionate expres-
sion of GABA(A) R dominates, while in the prefrontal
cortex and striatum, excessive GABA/glutamate ratios
are the hallmark of changes. These region-specific
changes provide complementary evidence to understand
the increased inhibitory tone found in our previous
neurophysiological work. In spite of a similar physio-
logical endpoint, the regional heterogeneity of molecular
changes suggests the need for region tailored therapies
directed to different phenotypes of autism.
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